145 related articles for article (PubMed ID: 32438599)
1. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.
Braun LM; Lagies S; Guenzle J; Fichtner-Feigl S; Wittel UA; Kammerer B
Cells; 2020 May; 9(5):. PubMed ID: 32438599
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
[TBL] [Abstract][Full Text] [Related]
3. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
[TBL] [Abstract][Full Text] [Related]
4. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
Parasido E; Avetian GS; Naeem A; Graham G; Pishvaian M; Glasgow E; Mudambi S; Lee Y; Ihemelandu C; Choudhry M; Peran I; Banerjee PP; Avantaggiati ML; Bryant K; Baldelli E; Pierobon M; Liotta L; Petricoin E; Fricke ST; Sebastian A; Cozzitorto J; Loots GG; Kumar D; Byers S; Londin E; DiFeo A; Narla G; Winter J; Brody JR; Rodriguez O; Albanese C
Mol Cancer Res; 2019 Sep; 17(9):1815-1827. PubMed ID: 31164413
[TBL] [Abstract][Full Text] [Related]
5. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
Awasthi N; Mikels-Vigdal AJ; Stefanutti E; Schwarz MA; Monahan S; Smith V; Schwarz RE
J Cell Mol Med; 2019 Jun; 23(6):3878-3887. PubMed ID: 30941918
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model.
Bressand D; Novell A; Girault A; Raoul W; Fromont-Hankard G; Escoffre JM; Lecomte T; Bouakaz A
Mol Pharm; 2019 Sep; 16(9):3814-3822. PubMed ID: 31356090
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
[TBL] [Abstract][Full Text] [Related]
10. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
[TBL] [Abstract][Full Text] [Related]
11. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ
J Exp Clin Cancer Res; 2024 Jan; 43(1):4. PubMed ID: 38163893
[TBL] [Abstract][Full Text] [Related]
13. [Nab-paclitaxel].
Lopez-Trabada Ataz D; Dumont S; André T
Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
Al-Batran SE; Geissler M; Seufferlein T; Oettle H
Oncol Res Treat; 2014; 37(3):128-34. PubMed ID: 24685917
[TBL] [Abstract][Full Text] [Related]
15. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of
Awasthi N; Schwarz MA; Zhang C; Schwarz RE
Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
[TBL] [Abstract][Full Text] [Related]
17. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
Michl P
Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
[No Abstract] [Full Text] [Related]
18. Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
Sebens Müerköster S; Werbing V; Sipos B; Debus MA; Witt M; Grossmann M; Leisner D; Kötteritzsch J; Kappes H; Klöppel G; Altevogt P; Fölsch UR; Schäfer H
Oncogene; 2007 Apr; 26(19):2759-68. PubMed ID: 17086212
[TBL] [Abstract][Full Text] [Related]
20. The winning formulation: the development of paclitaxel in pancreatic cancer.
Ma WW; Hidalgo M
Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]